Stella Diagnostics Inc (SLDX) Financiero

Stella Diagnostics, Inc. operates as a molecular diagnostics-based organization, which focuses on improving patient management strategies. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2003-07-29. The Company’s proprietary technology is based on rigorous research by domain experts and practicing physicians and can notify providers if common diseases of the esophagus like GERD and Barrett’s esophagus express proteins associated with normal or carcinogenic processes. Its panel of biomarkers and targeted proteomics method, the company can better inform gastroenterologists, surgical oncologists and pathologists which patients are high risk for disease progression into precancer or cancer. The predictive panel will be offered as a Laboratory Developed Test (LDT) in a CAP/CLIA Certified moderate complexity laboratory. Its subsidiaries include SLDX, Inc. and Galaxy Pharmaceuticals LLC.